Vaccibody to adopt IFRS and to explore a potential listing of its shares on the Nasdaq Global Market...
Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel vaccine and immunotherapies, announced today that its CFO, Lars Dencker Nielsen, is stepping down and will leave the Company at the end of the month. Vaccibody has retained a leading global executive...
Vaccibody reports promising preclinical data with a second-generation COVID-19 vaccine and announces its infectious disease strategy. View press release (PDF)...
Co-founder, President and CSO Agnete Fredriksen receives the Research Council of Norway’s Innovation Award View press release (PDF)...
Vaccibody to present at Jefferies Virtual Healthcare Conference View press release (PDF)...
Following the expiration of the HSR Act waiting period, the collaboration agreement with Genentech is now effective View press release (PDF)...
Vaccibody Lists on Oslo Stock Exchange’s Merkur Market View press release (PDF)...
Update on Expanded R&D Focus and Strategy View press release (PDF)...
Vaccibody enters into worldwide, exclusive license and collaboration agreement with Genentech to develop VB10.NEO, individualized neoantigen cancer vaccines View press release (PDF)...
QUARTERLY REPORT – 2020 Q2 (PDF)...